Ex-Novartis Cell & Gene Therapy Exec Chou Joins Aruvant as CEO

William Chou has been appointed CEO of Aruvant Sciences. Chou was most recently a vice president and global disease lead for the Novartis (NYSE: [[ticker:NVS]]) cell and gene therapy unit. Before Novartis, he worked at Boston Consulting Group. Aruvant, which splits its operations between New York and Basel, Switzerland, is developing therapies for severe blood disorders. The Roivant Sciences subsidiary’s lead candidate, ARU-1801, is an experimental gene therapy for sickle cell disease and beta thalassemia.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan